Sanofi
2 years ago ⋅ English ⋅ 5 min read
Newsroom
Media Update: Positive data from two Phase 3 Dupixent® (dupilumab) trials in prurigo nodularis published in Nature Medicine

Positive data from two Phase 3 Dupixent® (dupilumab) trials in prurigo nodularis published in Nature MedicineParis and Tarrytown, N.Y. May 8, 2023. Positive results from two Phase 3 Dup... Read More
Sanofi
2 years ago ⋅ English ⋅ 7 min read
Newsroom
Media Update: New late-breaking data at ATS 2023 demonstrate significant advancements across Dupixent® and broader respiratory pipeline

New late-breaking data at ATS 2023 demonstrate significant advancements across Dupixent® and broader respiratory pipeline- 17 abstracts showcase new data for Dupixent, itepekimab and an... Read More
Sanofi
2 years ago ⋅ English ⋅ 4 min read
Newsroom
Press Release: Sanofi completes acquisition of Provention Bio, Inc.

Sanofi completes acquisition of Provention Bio, Inc.Paris, April 27 2023. Sanofi announced today the completion of its acquisit i on of Provention Bio, Inc. (“Provention Bio”). The acqu... Read More
Sanofi
2 years ago ⋅ English ⋅ 4 min read
Newsroom
Sanofi completes acquisition of Provention Bio, Inc.

Sanofi completes acquisition of Provention Bio, Inc.Paris, April 27 2023. Sanofi announced today the completion of its acquisit i on of Provention Bio, Inc. (“Provention Bio”). The acqu... Read More
Sanofi
2 years ago ⋅ English ⋅ 2 min read
Newsroom
Strong Q1 growth driven by Specialty Care, Vaccines and CHC

Strong Q1 growth driven by Specialty Care, Vaccines and CHCQ1 2023 sales growth of 5.5% at CER and business EPS(1) growth of 11.9% at CER- Specialty Care grew 18.3% driven by Dupixent®... Read More
Sanofi
2 years ago ⋅ English ⋅ 2 min read
Newsroom
Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC

Strong Q1 growth driven by Specialty Care, Vaccines and CHCQ1 2023 sales growth of 5.5% at CER and business EPS(1) growth of 11.9% at CER- Specialty Care grew 18.3% driven by Dupixent®... Read More